Sodium zirconium cyclosilicate ZS-9 crystal and preparation method thereof

By adding specific additives to the preparation of ZS-9 cyclozirconium silicate crystal and performing high temperature stirring in a normal temperature autoclave, the problems of uneven material mixing and high equipment requirements in the existing process are solved, and high purity and regular particles are achieved The preparation is suitable for industrial production.

CN119038567APending Publication Date: 2024-11-29NANJING BIOZER PHARMATECH CO LTD

Patent Information

Application Number
CN202410909532.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-08
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

In the existing preparation process for the ZS-9 crystal form of zirconium cyclosilicate, the materials are mixed unevenly and impurity crystal forms are easily generated, making it difficult to obtain high-purity and regular particles, and the process equipment requirements are high and the adaptability is poor.

Method used

Use a conventional autoclave for high-temperature stirring at room temperature, add specific additives such as anhydrous citric acid, tartaric acid, etc. to make the zirconium reagent, silicon reagent and sodium hydroxide evenly mix, conduct a sealed high-temperature reaction, reduce equipment requirements, and simplify the process flow.

Benefits of technology

The preparation of ZS-9 crystals of ZS-9 cyclozirconium silicate with regular particles, uniform size and higher crystal purity is achieved. The process cycle is short, the cost is low, and the operation is simple, and it is suitable for industrial production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119038567A_ABST
    Figure CN119038567A_ABST
Patent Text Reader

Abstract

The invention belongs to the field of medicine crystals and preparation thereof, and particularly relates to a sodium zirconium cyclosilicate ZS-9 crystal and a preparation method thereof, by using the method, high-purity ZS-9 can be efficiently obtained, the product particle size is uniform, and the technological process is suitable for industrial production.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of drug crystals and preparation thereof, and particularly relates to a sodium zirconium cyclosilicate ZS-9 crystal and a preparation method thereof. Background Art

[0002] Sodium zirconium cyclosilicate powder (commercial name: Levitra) is a new oral potassium-lowering drug developed by AstraZeneca. On December 31, 2019, it was approved for marketing by the China National Medical Products Administration for the treatment of hyperkalemia in adults.

[0003] Hyperkalemia is one of the most common complications in patients with chronic kidney disease (CKD) and heart failure (HF). There are about 160 million CKD patients in my country, of which nearly 40% of end-stage CKD patients die from arrhythmia or cardiac arrest. The all-cause mortality rate of patients with hyperkalemia is 26 times that of people with normal blood potassium, and the mortality rate of patients with severe hyperkalemia can be as high as 30%.

[0004] In the past, the commonly used clinical treatment options for hyperkalemia included traditional intravenous drug therapy, oral potassium-lowering resins, and dialysis. Each of these treatments has its own limitations. For example, intravenous drug therapy cannot remove excess potassium ions in the body, and the efficacy is short-lived; potassium-lowering resins are slow to take effect and may cause serious gastrointestinal adverse reactions; dialysis treatment has the risk of recurrence, occupies a large amount of medical resources, and the blood potassium level rises after dialysis.

[0005] In addition, conventional medications for CKD and HF, such as renin-angiotensin-aldosterone system inhibitors (RAAs), also pose challenges to controlling blood potassium levels. RASSi treatment may cause elevated blood potassium levels in patients with heart failure, but if the dose is reduced or discontinued, it may lead to worsening heart failure and increased mortality, which puts treatment in a "dilemma." Therefore, it is urgent to find a solution that can effectively control blood potassium without affecting conventional treatment of heart failure.

[0006] Sodium zirconium cyclosilicate is a water-insoluble compound that uses innovative ion capture technology. It is highly selective for potassium ions and is not absorbed or metabolized by the human body. It is excreted from the body through feces, thereby achieving rapid potassium reduction and stabilizing blood potassium within a safe range for a long time.

[0007] The results of global clinical trials and a Chinese pharmacodynamic study showed that sodium zirconium cyclosilicate began to take effect one hour after taking the drug, and the median time to reach normal blood potassium levels was 2.2 hours. 98% of patients reached normal blood potassium levels within 48 hours. Nearly 90% of patients maintained serum potassium below 5.1mmol / L after one year of treatment, and had good long-term tolerance without serious adverse reactions.

[0008] Sodium zirconium cyclosilicate (ZS-9 crystal form) is a potassium binder. Studies have shown that ZS-9 is almost 100% selective for potassium ions, while sodium polystyrene sulfonate (SPS) prefers calcium ions to potassium ions and magnesium ions. ZS-9's ability to bind potassium ions is 10 times that of SPS.

[0009] Due to its unique mechanism of action and clinical efficacy, sodium zirconium cyclosilicate can help patients with hyperkalemia meet their unmet treatment needs. In the first half of 2019, it was included in the second batch of "List of Overseas New Drugs Urgently Needed in Clinical Practice" by the Drug Review Center (CDE) of the National Medical Products Administration and was given priority review and approval. In December 2019, it obtained marketing approval from the China National Medical Products Administration (NMPA) for the treatment of hyperkalemia in adults.

[0010] The common process of sodium zirconium cyclosilicate ZS-9 crystal form disclosed in the prior art is: zirconium reagent, silicon reagent, alkali and water are mixed together and reacted under high pressure and high temperature to obtain ZS-9 crystal form, but in this process, a large amount of solids are precipitated when several materials are mixed, the reaction system is not uniform, and impurity crystal forms are easily produced, making it difficult to obtain ZS-9 crystal form with higher purity. Chinese patent CN201380042557.5 and others disclose that in order to make the system mixed evenly, a baffle must be added at a suitable position of the autoclave to facilitate material mixing, so as to obtain ZS-9 crystal form with higher purity; but even so, the particle shape and particle size of the product under a microscope are different.

[0011] The inventor of the present application unexpectedly discovered a new sodium zirconium cyclosilicate ZS-9 crystal and its preparation method in the research. A specific additive is added to the reaction system, and the mixture is evenly mixed in a conventional reaction device at room temperature, and the mixture is heated and stirred in a conventional autoclave, or even stirred without stirring, to obtain pure sodium zirconium cyclosilicate ZS-9 crystals with good crystal state and regular particles, so that the process is easy to scale up, and the filtering and drying of the produced materials are more convenient and quick. Compared with the existing disclosed processes, the process equipment requirements are lower, which is conducive to obtaining products with regular particles, uniform size and higher crystal purity. Summary of the invention

[0012] On the one hand, the present invention provides a sodium zirconium cyclosilicate ZS-9 crystal, characterized in that the crystal is a cubic crystal, the ratio between the length and width of the cubic crystal is 1:0.8 to 1:1.2, and the ratio between the length and height is 1:0.8 to 1:1.2.

[0013] In certain embodiments of the present invention, the ratio between the length and width of the cubic crystal is 1:0.8, 1:0.9, 1:1, 1:1.1, 1:1.2.

[0014] In certain embodiments of the present invention, the ratio between the length and the height of the cubic crystal is 1:0.8, 1:0.9, 1:1, 1:1.1, 1:1.2.

[0015] In certain embodiments of the present invention, the crystals contain no less than 50% by mass, preferably 55%, preferably 60%, preferably 65%, preferably 70%, preferably 75%, preferably 80%, preferably 85%, preferably 90%, preferably 95% by mass of the aforementioned cubic crystals.

[0016] In certain embodiments of the present invention, the average particle size of the cubic crystals is 0.5 μm-20 μm.

[0017] In certain embodiments of the present invention, the average particle size of the cubic crystals is 0.5 μm, 1 μm, 5 μm, 10 μm, 15 μm, or 20 μm.

[0018] On the other hand, the present invention also provides a method for preparing sodium zirconium cyclosilicate ZS-9 crystals, characterized in that a specific additive is added to the conventional preparation method of ZS-9.

[0019] The conventional preparation method is a method for preparing sodium zirconium cyclosilicate ZS-9 disclosed in the prior art, such as a method for preparing sodium zirconium cyclosilicate ZS-9 using a zirconium reagent, a silicon reagent and / or sodium hydroxide.

[0020] In certain embodiments of the present invention, the additive is selected from one or more of anhydrous citric acid, citric acid monohydrate, tartaric acid, malic acid, glutamic acid, succinic acid, ethylenediaminetetraacetic acid, 4-aminobutyric acid, 1,3-propylenediamine and pharmaceutically acceptable salts thereof; preferably, the additive is selected from one or more of anhydrous citric acid, citric acid monohydrate, tartaric acid and malic acid.

[0021] In certain embodiments of the present invention, the molar ratio of the additive to the zirconium reagent added in the conventional preparation method is 0.3:1 to 2.5:1, preferably 0.5:1 to 2.0:1, and more preferably 0.75:1 to 1.75:1.

[0022] In certain embodiments of the present invention, the molar ratio of the additive to the zirconium reagent added in the conventional preparation method is 0.5:1, 0.8:1, 1:1, 1.5:1, 1.75:1, 2:1, or 2.5:1.

[0023] More specifically, the present invention provides a method for preparing sodium zirconium cyclosilicate ZS-9 crystals, characterized in that the preparation method comprises: mixing a zirconium reagent, an additive, a silicon reagent, sodium hydroxide and water into a solution, sealing and reacting at a high temperature, cooling and filtering after the reaction is completed, to obtain sodium zirconium cyclosilicate ZS-9.

[0024] In certain embodiments of the present invention, the zirconium reagent is selected from one or more of zirconium acetate solution, zirconium oxychloride octahydrate, zirconium chloride and zirconium sulfate tetrahydrate. Preferably, the zirconium reagent is selected from one or more of zirconium acetate solution and zirconium oxychloride octahydrate.

[0025] In certain embodiments of the present invention, the additive is selected from one or more of anhydrous citric acid, citric acid monohydrate, tartaric acid, malic acid, glutamic acid, succinic acid, ethylenediaminetetraacetic acid, 4-aminobutyric acid, 1,3-propylenediamine and pharmaceutically acceptable salts thereof; preferably, the additive is selected from one or more of anhydrous citric acid, citric acid monohydrate, tartaric acid and malic acid.

[0026] In certain embodiments of the present invention, the silicon reagent is selected from one or more of anhydrous Na2SiO3, Na2SiO3 hydrate, Na2SiO3 aqueous solution, anhydrous Na2Si3O7, Na2Si3O7 aqueous solution, and silicon dioxide; preferably, the silicon reagent is selected from silicon dioxide.

[0027] The zirconium reagent and the silicon reagent are solutions, which are commercially available or prepared solutions with suitable viscosity and concentration.

[0028] In certain embodiments of the present invention, the molar ratio of the additive to the zirconium reagent is 0.3:1 to 2.5:1, preferably 0.5:1 to 2.0:1, and more preferably 0.75:1 to 1.75:1.

[0029] In certain embodiments of the present invention, the molar ratio of the additive to the zirconium reagent added in the conventional preparation method is 0.5:1, 0.8:1, 1:1, 1.5:1, 1.75:1, 2:1, or 2.5:1.

[0030] In certain embodiments of the present invention, the molar ratio of the silicon reagent to the zirconium reagent is 3:1 to 10:1, preferably 3:1 to 6:1.

[0031] In certain embodiments of the present invention, the molar ratio of the silicon reagent to the zirconium reagent is 3:1, 4:1, 5:1, 6:1, 7:1, or 8:1.

[0032] In certain embodiments of the present invention, the molar ratio of the sodium hydroxide to the zirconium reagent is 2:1 to 18:1, preferably 7:1 to 14:1.

[0033] In certain embodiments of the present invention, the molar ratio of the sodium hydroxide to the zirconium reagent is 7:1, 8:1, 10:1, 12:1, 13:1, or 14:1.

[0034] In certain embodiments of the present invention, the weight ratio of the water to the zirconium reagent is 2:1 to 20:1, preferably 5:1 to 15:1.

[0035] In certain embodiments of the present invention, the weight ratio of the water to the zirconium reagent is 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 15:1, or 20:1.

[0036] In certain embodiments of the present invention, the sealing reaction temperature at high temperature is 150-300° C., preferably 175-275° C.; the reaction time is 1-72 h, preferably 2-60 h, and more preferably 4-46 h.

[0037] In certain embodiments of the present invention, the closed high temperature reaction temperature is 175°C, 200°C, 225°C, or 250°C.

[0038] In certain embodiments of the present invention, the closed high temperature reaction time is 6h, 12h, 18h, 24h, 30h, 36h, 42h, 48h, 54h, 60h, 66h, or 72h.

[0039] In certain embodiments of the present invention, sodium zirconium cyclosilicate ZS-9 seed crystals are added to the reaction system.

[0040] Preferably, ZS-9 seed crystals with a yield of 0.01% to 20%, preferably 0.02% to 10%, and preferably 0.05% to 5% are added.

[0041] In certain embodiments of the invention, 0.05%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5% or 5% ZS-9 seeds are added.

[0042] The percentages in the examples are by mass unless otherwise specified.

[0043] Unless otherwise specified, all numbers used in this specification and claims to indicate content, concentration, ratio, weight, percentage, technical effect, etc. should be understood as modified by the term "about" or "approximately" in any case. "About" represents a range of ±10% of the value it modifies, preferably a range of ±5%.

[0044] Beneficial Effects

[0045] The invention provides a new method for preparing sodium zirconium cyclosilicate ZS-9 crystals. By adding additives into a reaction solution, a zirconium reagent, an additive, a silicon reagent and sodium hydroxide can be easily mixed evenly; and then a high-temperature and high-pressure reaction is carried out. Compared with previous literature reports and patents, the mixing uniformity of the reaction materials is significantly improved, which is conducive to obtaining a product with regular particles, uniform size and higher crystal purity.

[0046] Moreover, compared with the prior art, the new method has significantly lower requirements for high-pressure reaction equipment, and a conventional autoclave can be used for closed high-temperature reactions, without the need for a special stirring device, or even without a stirring device.

[0047] In summary, the technical solution provided by the present invention has a short cycle, low cost, simple operation, low environmental pollution, and is suitable for industrial production. BRIEF DESCRIPTION OF THE DRAWINGS

[0048] Figure 1 XRPD spectrum of the product of Example 1

[0049] Figure 2 This is the microscopic properties of the product of Example 1

[0050] Figure 3 XRPD spectrum of the original product of Comparative Example 1

[0051] Figure 4 This is the properties of the original product of comparative example 1 under a microscope

[0052] Figure 5 XRPD spectrum of the product without additives in Comparative Example 2

[0053] Figure 6 This is the microscopic properties of the product of Comparative Example 2 without using additives

[0054] Figure 7 XRPD spectrum of the product without additives in Comparative Example 3

[0055] Figure 8 This is the microscopic properties of the product of Comparative Example 3 without using additives DETAILED DESCRIPTION

[0056] The technical scheme of the present invention will be further described in detail below in conjunction with specific embodiments. It should be understood that the following embodiments are only exemplary descriptions and explanations of the present invention and should not be construed as limiting the scope of protection of the present invention. All technologies implemented based on the above content of the present invention are included in the scope that the present invention is intended to protect.

[0057] Unless otherwise specified, the raw materials and reagents used in the following examples are commercially available or can be prepared by known methods.

[0058] Example 1

[0059] 1.98 g of anhydrous citric acid, 5 ml of water and 3.0 ml of zirconium acetate solution (containing about 16% zirconium) were mixed and dissolved, and 1.7 ml of 50% sodium hydroxide aqueous solution was added to obtain reaction solution A; 6.0 ml of Na2Si3O7 solution (containing about 12% silicon), 1.5 ml of 50% sodium hydroxide aqueous solution and 10 ml of water were mixed to obtain reaction solution B;

[0060] Add reaction liquid A to reaction liquid B, stir and mix evenly, add seed crystals, and then transfer to an autoclave. React at 240-250°C for about 58 hours without stirring, cool and filter, wash the filter cake with water, and dry to obtain the product. The product was sent for XRPD inspection, which showed that the crystal form was sodium zirconium cyclosilicate ZS-9; the average crystal particle size was about 9.0um, the aspect ratio was about 1:1, the length-to-height ratio was about 1:1, and the three-dimensional crystal content was about 95%. The XRPD spectrum is attached Figure 1 , product particles under microscope Figure 2 .

[0061] Example 2

[0062] 1.61 g of zirconium oxychloride octahydrate, 1.58 g of citric acid monohydrate and 1.6 ml of water were mixed and dissolved, and then sodium hydroxide aqueous solution (1.30 g of sodium hydroxide and 2.6 ml of water) was added to obtain reaction solution A; 1.20 g of silicon dioxide, 1.60 g of sodium hydroxide and 11.8 ml of water were mixed to obtain reaction solution B;

[0063] The reaction liquid A was added to the reaction liquid B, stirred and mixed evenly, and then transferred to the autoclave, without stirring, reacted at 200 degrees for 40 hours, cooled and filtered, and the filter cake was washed with water and dried to obtain 1.71g of the product. The product was sent for XRPD inspection, which showed that the crystal form was sodium zirconium cyclosilicate ZS-9; the average crystal particle size was about 4.0um, the aspect ratio was about 1:1, the length-to-height ratio was about 1:1, and the three-dimensional crystal content was greater than 90%; the XRPD spectrum was the same as the attached Figure 1 , the product particle picture under the microscope is the same Figure 2 .

[0064] Example 3

[0065] 3.20 g of zirconium oxychloride octahydrate, 3.20 g of citric acid monohydrate and 10 ml of water were mixed and dissolved, and then 8.0 g of 50% sodium hydroxide aqueous solution was added to obtain reaction solution A; 14.2 g of Na2SiO 3· 9H2O and 7ml water were mixed to obtain reaction solution B;

[0066] The reaction liquid A is added to the reaction liquid B, stirred and mixed evenly, seed crystals are added, and then transferred to an autoclave, reacted at about 140°C for about 24 hours without stirring, and then reacted at about 240°C for about 24 hours, cooled and filtered, and the filter cake is washed with water and dried to obtain the product. The product was sent for XRPD inspection, which showed that the crystal form was sodium zirconium cyclosilicate ZS-9; the average crystal particle size was about 0.5um, the aspect ratio was about 1:1, the length-to-height ratio was about 1:1, and the three-dimensional crystal content was greater than 95%; the XRPD spectrum is the same as the attached Figure 1 , the product particle picture under the microscope is the same Figure 2 .

[0067] Example 4

[0068] 1.17 g zirconium chloride, 1.58 g citric acid monohydrate and 3.2 ml water were mixed and dissolved, and then sodium hydroxide aqueous solution (1.70 g sodium hydroxide + 2.6 ml water) was added to obtain reaction solution A; 1.19 g silicon dioxide, 1.60 g sodium hydroxide and 11.8 ml water were mixed to obtain reaction solution B;

[0069] Add reaction liquid A to reaction liquid B, stir and mix evenly, add seed crystals, and then transfer to an autoclave. React at about 200°C without stirring for about 24 hours, cool and filter, wash the filter cake with water, and dry to obtain the product. The product was sent for XRPD inspection, which showed that the crystal form was sodium zirconium cyclosilicate ZS-9; the average crystal particle size was about 1.0um, the aspect ratio was about 1:1, the length-to-height ratio was about 1:1, and the three-dimensional crystal content was greater than 90%; the XRPD spectrum was the same as the attached Figure 1 , the product particle picture under the microscope is the same Figure 2 .

[0070] Example 5

[0071] 1.78 g of zirconium sulfate tetrahydrate, 1.58 g of citric acid monohydrate and 1.6 ml of water were mixed and dissolved, and then sodium hydroxide aqueous solution (1.70 g of sodium hydroxide + 2.6 ml of water) was added to obtain reaction solution A; 1.19 g of silicon dioxide, 1.60 g of sodium hydroxide and 11.8 ml of water were mixed to obtain reaction solution B;

[0072] Add reaction liquid A to reaction liquid B, stir and mix evenly, add seed crystals, and then transfer to an autoclave. React at about 200°C without stirring for about 24 hours, cool and filter, wash the filter cake with water, and dry to obtain the product. The product was sent for XRPD inspection, which showed that the crystal form was sodium zirconium cyclosilicate ZS-9; the average crystal particle size was about 0.5um, the aspect ratio was about 1:1, the length-to-height ratio was about 1:1, and the three-dimensional crystal content was greater than 95%; the XRPD spectrum was the same as the attached Figure 1 , the product particle picture under the microscope is the same Figure 2 .

[0073] Example 6

[0074] 1.60 g of zirconium oxychloride octahydrate, 1.57 g of citric acid monohydrate and 1.6 ml of water were mixed and dissolved, and then 3.9 g of 33% sodium hydroxide aqueous solution was added to obtain reaction solution A; 2.02 g of anhydrous Na2Si3O7 solid, 1.06 g of sodium hydroxide and 12 ml of water were mixed to obtain reaction solution B;

[0075] Add reaction liquid A to reaction liquid B, stir and mix evenly, add seed crystals, and then transfer to an autoclave. React at 200-210°C without stirring for about 37 hours, cool and filter, wash the filter cake with water, and dry to obtain the product. The product was sent for XRPD inspection, which showed that the crystal form was sodium zirconium cyclosilicate ZS-9; the average crystal particle size was about 2.0um, the aspect ratio was about 1:1, the length-to-height ratio was about 1:1, and the three-dimensional crystal content was greater than 95%; the XRPD spectrum was the same as the attached Figure 1 , the product particle picture under the microscope is the same Figure 2 .

[0076] Example 7

[0077] 1.60 g of zirconium oxychloride octahydrate, 1.57 g of citric acid monohydrate and 1.6 ml of water were mixed and dissolved, and then 3.9 g of 33% sodium hydroxide aqueous solution was added to obtain reaction solution A; 2.63 g of anhydrous Na2SiO3 solid and 12 ml of water were mixed to obtain reaction solution B;

[0078] Add reaction liquid A to reaction liquid B, stir and mix evenly, add seed crystals, and then transfer to an autoclave. React at 200-210°C without stirring for about 37 hours, cool and filter, wash the filter cake with water, and dry to obtain the product. The product was sent for XRPD inspection, which showed that the crystal form was sodium zirconium cyclosilicate ZS-9; the average crystal particle size was about 1.8um, the aspect ratio was about 1:1, the length-to-height ratio was about 1:1, and the three-dimensional crystal content was greater than 90%; the XRPD spectrum was the same as the attached Figure 1 , the product particle picture under the microscope is the same Figure 2 .

[0079] Example 8

[0080] 1.60 g zirconium oxychloride octahydrate, 1.57 g citric acid monohydrate and 1.6 ml water were mixed and dissolved, and then 3.9 g 33% sodium hydroxide aqueous solution was added to obtain reaction solution A; 4.44 g Na2SiO 3· 5H2O solid and 10.2ml water were mixed to obtain reaction solution B;

[0081] Add reaction liquid A to reaction liquid B, stir and mix evenly, add seed crystals, and then transfer to an autoclave. React at 200-210°C without stirring for about 37 hours, cool and filter, wash the filter cake with water, and dry to obtain the product. The product was sent for XRPD inspection, which showed that the crystal form was sodium zirconium cyclosilicate ZS-9; the average crystal particle size was about 1.5um, the aspect ratio was about 1:1, the length-to-height ratio was about 1:1, and the three-dimensional crystal content was greater than 95%; the XRPD spectrum was the same as the attached Figure 1 , the product particle picture under the microscope is the same Figure 2 .

[0082] Example 9

[0083] 1.61 g of zirconium oxychloride octahydrate, 1.13 g of tartaric acid and 3.2 ml of water were mixed and dissolved, and then 3.6 g of 28% sodium hydroxide aqueous solution was added to obtain reaction solution A; 1.20 g of silicon dioxide, 1.60 g of sodium hydroxide and 12 ml of water were mixed to obtain reaction solution B;

[0084] Add reaction liquid A to reaction liquid B, stir and mix evenly, add seed crystals, and then transfer to an autoclave. React at 200-210°C without stirring for about 25 hours, cool and filter, wash the filter cake with water, and dry to obtain the product. The product was sent for XRPD inspection, which showed that the crystal form was sodium zirconium cyclosilicate ZS-9; the average crystal particle size was about 0.6um, the aspect ratio was about 1:1, the length-to-height ratio was about 1:1, and the three-dimensional crystal content was greater than 95%; the XRPD spectrum was the same as the attached Figure 1 , the product particle picture under the microscope is the same Figure 2 .

[0085] Example 10

[0086] 1.61 g of zirconium oxychloride octahydrate, 1.46 g of EDTA and 3.2 ml of water were mixed and dissolved, and then 3.6 g of 28% sodium hydroxide aqueous solution was added to obtain reaction solution A; 1.20 g of silicon dioxide, 1.60 g of sodium hydroxide and 12 ml of water were mixed to obtain reaction solution B;

[0087] Add reaction liquid A to reaction liquid B, stir and mix evenly, add seed crystals, and then transfer to an autoclave. React at 200-210°C without stirring for about 25 hours, cool and filter, wash the filter cake with water, and dry to obtain the product. The product was sent for XRPD inspection, which showed that the crystal form was sodium zirconium cyclosilicate ZS-9; the average crystal particle size was about 0.8um, the aspect ratio was about 1:1, the length-to-height ratio was about 1:1, and the three-dimensional crystal content was greater than 95%; the XRPD spectrum was the same as the attached Figure 1 , the product particle picture under the microscope is the same Figure 2 .

[0088] Embodiment 11

[0089] 1.60 g of zirconium oxychloride octahydrate, 1.01 g of malic acid and 2.6 ml of water were mixed and dissolved, and then 2.5 g of 40% sodium hydroxide aqueous solution was added to obtain reaction solution A; 1.20 g of silicon dioxide, 1.60 g of sodium hydroxide and 11 ml of water were mixed to obtain reaction solution B;

[0090] Add reaction liquid A to reaction liquid B, stir and mix evenly, add seed crystals, and then transfer to an autoclave. React at 200-210°C without stirring for about 24 hours, cool and filter, wash the filter cake with water, and dry to obtain the product. The product was sent for XRPD inspection, which showed that the crystal form was sodium zirconium cyclosilicate ZS-9; the average crystal particle size was about 1.0um, the aspect ratio was about 1:1, the length-to-height ratio was about 1:1, and the three-dimensional crystal content was greater than 95%; the XRPD spectrum was the same as the attached Figure 1 , the product particle picture under the microscope is the same Figure 2 .

[0091] Example 12

[0092] 1.60 g of zirconium oxychloride octahydrate, 1.10 g of glutamic acid and 2.6 ml of water were mixed to form a solution, and then 2.5 g of 40% sodium hydroxide aqueous solution was added to obtain reaction solution A; 1.20 g of silicon dioxide, 1.60 g of sodium hydroxide and 11 ml of water were mixed to obtain reaction solution B;

[0093] Add reaction liquid A to reaction liquid B, stir and mix evenly, add seed crystals, and then transfer to an autoclave. React at 200-210°C without stirring for about 24 hours, cool and filter, wash the filter cake with water, and dry to obtain the product. The product was sent for XRPD inspection, which showed that the crystal form was sodium zirconium cyclosilicate ZS-9; the average crystal particle size was about 1.0um, the aspect ratio was about 1:1, the length-to-height ratio was about 1:1, and the three-dimensional crystal content was greater than 95%; the XRPD spectrum was the same as the attached Figure 1 , the product particle picture under the microscope is the same Figure 2 .

[0094] Example 13

[0095] 1.60 g of zirconium oxychloride octahydrate, 0.89 g of succinic acid and 2.6 ml of water were mixed and dissolved, and then 2.5 g of 40% sodium hydroxide aqueous solution was added to obtain reaction solution A; 1.20 g of silicon dioxide, 1.60 g of sodium hydroxide and 11 ml of water were mixed to obtain reaction solution B;

[0096] Add reaction liquid A to reaction liquid B, stir and mix evenly, add seed crystals, and then transfer to an autoclave. React at 200-210°C without stirring for about 24 hours, cool and filter, wash the filter cake with water, and dry to obtain the product. The product was sent for XRPD inspection, which showed that the crystal form was sodium zirconium cyclosilicate ZS-9; the average crystal particle size was about 1.0um, the aspect ratio was about 1:1, the length-to-height ratio was about 1:1, and the three-dimensional crystal content was greater than 95%; the XRPD spectrum was the same as the attached Figure 1 , the product particle picture under the microscope is the same Figure 2 .

[0097] Embodiment 14

[0098] 1.60 g of zirconium oxychloride octahydrate, 0.77 g of 4-aminobutyric acid and 2.6 ml of water were mixed and dissolved, and then 2.2 g of 32% sodium hydroxide aqueous solution was added to obtain reaction solution A; 1.20 g of silicon dioxide, 1.60 g of sodium hydroxide and 11 ml of water were mixed to obtain reaction solution B;

[0099] Add reaction liquid A to reaction liquid B, stir and mix evenly, add seed crystals, and then transfer to an autoclave. React at 200-210°C without stirring for about 24 hours, cool and filter, wash the filter cake with water, and dry to obtain the product. The product was sent for XRPD inspection, which showed that the crystal form was sodium zirconium cyclosilicate ZS-9; the average crystal particle size was about 0.5um, the aspect ratio was about 1:1, the length-to-height ratio was about 1:1, and the three-dimensional crystal content was greater than 95%; the XRPD spectrum was the same as the attached Figure 1 , the product particle picture under the microscope is the same Figure 2 .

[0100] Embodiment 15

[0101] 1.60 g of zirconium oxychloride octahydrate, 0.56 g of 1,3-propylenediamine and 2.6 ml of water were mixed and dissolved, and 1.9 g of 21% sodium hydroxide aqueous solution was added to obtain reaction solution A; 1.20 g of silicon dioxide, 1.60 g of sodium hydroxide and 11 ml of water were mixed to obtain reaction solution B;

[0102] Add reaction liquid A to reaction liquid B, stir and mix evenly, add seed crystals, and then transfer to an autoclave. React at 200-210°C without stirring for about 24 hours, cool and filter, wash the filter cake with water, and dry to obtain the product. The product was sent for XRPD inspection, which showed that the crystal form was sodium zirconium cyclosilicate ZS-9; the average crystal particle size was about 1.5um, the aspect ratio was about 1:1, the length-to-height ratio was about 1:1, and the three-dimensional crystal content was greater than 95%; the XRPD spectrum was the same as the attached Figure 1 , the product particle picture under the microscope is the same Figure 2 .

[0103] Example 16

[0104] 1.60 g of zirconium oxychloride octahydrate, 1.57 g of citric acid monohydrate and 1.6 ml of water were mixed and dissolved, and then sodium hydroxide aqueous solution (1.29 g of sodium hydroxide and 2.6 ml of water) was added to obtain reaction solution A; 0.90 g of silicon dioxide, 1.20 g of sodium hydroxide and 10 ml of water were mixed to obtain reaction solution B;

[0105] The reaction liquid A was added to the reaction liquid B, stirred and mixed evenly, seed crystals were added, and then transferred to an autoclave, reacted at 230°C for about 24 hours without stirring, cooled and filtered, and the filter cake was washed with water and dried to obtain 1.72g of the product. The product was sent for XRPD inspection, which showed that the crystal form was sodium zirconium cyclosilicate ZS-9; the average crystal particle size was about 0.8um, the aspect ratio was about 1:1, the length-to-height ratio was about 1:1, and the three-dimensional crystal content was greater than 95%; the XRPD spectrum was the same as the attached Figure 1 , the product particle picture under the microscope is the same Figure 2 .

[0106] Embodiment 17

[0107] 1.60 g of zirconium oxychloride octahydrate, 1.57 g of citric acid monohydrate and 1.6 ml of water were mixed and dissolved, and then sodium hydroxide aqueous solution (1.29 g of sodium hydroxide and 2.6 ml of water) was added to obtain reaction solution A; 1.79 g of silicon dioxide, 2.39 g of sodium hydroxide and 11.8 ml of water were mixed to obtain reaction solution B;

[0108] The reaction liquid A was added to the reaction liquid B, stirred and mixed evenly, seed crystals were added, and then transferred to an autoclave, reacted at 200°C for about 40 hours without stirring, cooled and filtered, and the filter cake was washed with water and dried to obtain 1.86g of the product. The product was sent for XRPD inspection, which showed that the crystal form was sodium zirconium cyclosilicate ZS-9; the average crystal particle size was about 0.5um, the aspect ratio was about 1:1, the length-to-height ratio was about 1:1, and the three-dimensional crystal content was greater than 95%; the XRPD spectrum was the same as the attached Figure 1 , the product particle picture under the microscope is the same Figure 2 .

[0109] Embodiment 18

[0110] 10.0 g of zirconium oxychloride octahydrate, 4.89 g of citric acid monohydrate and 10 ml of water were mixed and dissolved, and then sodium hydroxide aqueous solution (5.28 g of sodium hydroxide and 10 ml of water) was added to obtain reaction solution A; 14.9 g of silicon dioxide, 11.2 g of sodium hydroxide and 30 ml of water were mixed to obtain reaction solution B;

[0111] Add reaction liquid A to reaction liquid B, stir and mix evenly, add seed crystals, take about 1 / 3 volume of reaction liquid and transfer to autoclave, react at 225℃ for about 18 hours without stirring, cool and filter, wash the filter cake with water and dry to obtain 4.1g of product. The product was sent for XRPD inspection, which showed that the crystal form was sodium zirconium cyclosilicate ZS-9; the average crystal particle size was about 3.0um, the aspect ratio was about 1:1, the length-to-height ratio was about 1:1, and the three-dimensional crystal content was greater than 90%; the XRPD spectrum was the same as the attached Figure 1 , the product particle picture under the microscope is the same Figure 2 .

[0112] Embodiment 19

[0113] 30.0 g of zirconium oxychloride octahydrate, 24.5 g of citric acid monohydrate and 30 ml of water were mixed and dissolved, and then sodium hydroxide aqueous solution (21.4 g of sodium hydroxide and 30 ml of water) was added to obtain reaction solution A; 14.9 g of silicon dioxide, 11.2 g of sodium hydroxide and 30 ml of water were mixed to obtain reaction solution B;

[0114] Add reaction liquid A to reaction liquid B, stir and mix evenly, then add 390 ml of water, add seed crystals, take about 1 / 30 volume of reaction liquid and transfer to autoclave, react at 225°C for about 18 hours without stirring, cool and filter, wash the filter cake with water, and dry to obtain 1.31 g of product. The product was sent for XRPD inspection, which showed that the crystal form was sodium zirconium cyclosilicate ZS-9; the average crystal particle size was about 3.3 um, the aspect ratio was about 1:1, the length-to-height ratio was about 1:1, and the three-dimensional crystal content was greater than 90%; the XRPD spectrum was the same as the attached Figure 1 , the product particle picture under the microscope is the same Figure 2 .

[0115] Embodiment 20

[0116] 1.60 g of zirconium oxychloride octahydrate, 1.57 g of citric acid monohydrate and 1.6 ml of water were mixed and dissolved, and then sodium hydroxide aqueous solution (1.29 g of sodium hydroxide and 2.6 ml of water) was added to obtain reaction solution A; 1.19 g of silicon dioxide, 1.59 g of sodium hydroxide and 11.8 ml of water were mixed to obtain reaction solution B;

[0117] The reaction liquid A was added to the reaction liquid B, stirred and mixed evenly, seed crystals were added, and then transferred to the autoclave, reacted at 175 degrees without stirring for 16 hours, cooled and filtered, the filter cake was washed with water, and dried to obtain 1.76g of the product. The product was sent for XRPD inspection, which showed that the crystal form was sodium zirconium cyclosilicate ZS-9; the average crystal particle size was about 1.3um, the aspect ratio was about 1:1, the length-to-height ratio was about 1:1, and the three-dimensional crystal content was greater than 90%; the XRPD spectrum was the same as the attached Figure 1 , the product particle picture under the microscope is the same Figure 2 .

[0118] Embodiment 21

[0119] 1.60 g of zirconium oxychloride octahydrate, 1.57 g of citric acid monohydrate and 1.6 ml of water were mixed to form a solution, and then a sodium hydroxide aqueous solution (1.29 g of sodium hydroxide and 2.6 ml of water) was added dropwise to obtain a reaction solution A; 1.19 g of silicon dioxide, 1.59 g of sodium hydroxide and 11.8 ml of water were mixed to obtain a reaction solution B;

[0120] Add reaction liquid A to reaction liquid B, stir and mix evenly, add seed crystals, and then transfer to an autoclave, react at 275 degrees for 46 hours with an anchor stirring paddle at 150 rpm, cool and filter, wash the filter cake with water, and dry to obtain 2.24g of product. The product was sent for XRPD inspection, which showed that the crystal form was sodium zirconium cyclosilicate ZS-9; the average crystal particle size was about 1.8um, the aspect ratio was about 1:1, the length-to-height ratio was about 1:1, and the three-dimensional crystal content was greater than 95%; the XRPD spectrum is the same as the attached Figure 1 , the product particle picture under the microscope is the same Figure 2 .

[0121] Embodiment 22

[0122] 1.60 g of zirconium oxychloride octahydrate, 1.25 g of citric acid monohydrate and 1.6 ml of water were mixed and dissolved, and then sodium hydroxide aqueous solution (1.03 g of sodium hydroxide and 2.0 ml of water) was added to obtain reaction solution A; 0.96 g of silicon dioxide, 1.27 g of sodium hydroxide and 9.5 ml of water were mixed to obtain reaction solution B;

[0123] Add reaction liquid A to reaction liquid B, stir and mix evenly, add seed crystals, and then transfer to an autoclave, react at 200 degrees for 4 hours with an anchor stirring paddle at 150 rpm, cool and filter, wash the filter cake with water, and dry to obtain 1.81g of product. The product was sent for XRPD inspection, which showed that the crystal form was sodium zirconium cyclosilicate ZS-9; the average crystal particle size was about 0.5um, the aspect ratio was about 1:1, the length-to-height ratio was about 1:1, and the three-dimensional crystal content was greater than 95%; the XRPD spectrum is the same as the attached Figure 1 , the product particle picture under the microscope is the same Figure 2 .

[0124] Embodiment 23

[0125] 1.60 g of zirconium oxychloride octahydrate, 1.83 g of citric acid monohydrate and 1.6 ml of water were mixed to form reaction solution A; 1.42 g of sodium metasilicate nonahydrate, 0.40 g of sodium hydroxide and 1.8 ml of water were mixed to form reaction solution B;

[0126] The reaction liquid A was added to the reaction liquid B, stirred and mixed evenly, seed crystals were added, and then transferred to an autoclave, reacted at 250°C for about 20 hours without stirring, cooled and filtered, and the filter cake was washed with water and dried to obtain 1.82g of the product. The product was sent for XRPD inspection, which showed that the crystal form was sodium zirconium cyclosilicate ZS-9; the XRPD spectrum is attached Figure 1 , the product particle picture under the microscope is the same Figure 2 .

[0127] Embodiment 24

[0128] 1.61 g of zirconium oxychloride octahydrate, 1.59 g of citric acid monohydrate and 3.2 ml of water were mixed to obtain reaction solution A; 1.65 g of silicon dioxide, 3.50 g of sodium hydroxide and 12.8 ml of water were mixed to obtain reaction solution B;

[0129] The reaction liquid A was added to the reaction liquid B, stirred and mixed evenly, seed crystals were added, and then transferred to an autoclave, reacted at 225°C for about 20 hours without stirring, cooled and filtered, and the filter cake was washed with water and dried to obtain 1.66g of the product. The product was sent for XRPD inspection, which showed that the crystal form was sodium zirconium cyclosilicate ZS-9; the XRPD spectrum is attached Figure 1 , the product particle picture under the microscope is the same Figure 2 .

[0130] Comparative Example 1

[0131] Referring to the original patent CN103534209A Example 13, sodium zirconium cyclosilicate ZS-9 was prepared. The XRPD spectrum is attached. Figure 3 , product particles under microscope Figure 4 .

[0132] Comparative Example 2

[0133] 1.6 g of zirconium oxychloride octahydrate and 1.6 ml of water were mixed to form a clear reaction solution A; 0.89 g of silicon dioxide, 1.50 g of sodium hydroxide and 4.8 ml of water were mixed and stirred to form a clear reaction solution B;

[0134] Solution A was added to solution B, stirred and mixed evenly, seed crystals were added, and the mixture was transferred to an autoclave, stirred at 150 rpm using a general anchor stirring paddle, and reacted at 225°C for 20 hours; the mixture was cooled and filtered, and the filter cake was washed with water and dried to obtain 1.66 g of solid; XRPD showed that the main crystalline form was ZS-9, containing impurity crystalline forms ZS-7 and ZS-11, and the XRPD spectrum was attached. Figure 5 , product particles under microscope Figure 6 .

[0135] Comparative Example 3

[0136] 5.00 kg of zirconium oxychloride octahydrate and 10.0 L of water were mixed to form a clear reaction liquid A; 4.65 kg of silicon dioxide, 4.97 kg of sodium hydroxide and 30.0 L of water were mixed and stirred to form a clear reaction liquid B;

[0137] Solution A was added to solution B, stirred and mixed evenly, 250 g of seed crystals were added, and then transferred to an autoclave, stirred at 150 rpm using a general anchor stirring paddle, and reacted at 215°C for 20 hours; cooled and filtered, the filter cake was washed with water and dried to obtain 7.02 kg of solid; XRPD showed that the main crystal forms were ZS-9 and ZS-7, and contained more amorphous, the XRPD spectrum is attached Figure 7, product particles under microscope Figure 8 .

[0138] Comparative Example 4

[0139] 3.0 ml of zirconium acetate acetic acid solution (containing about 15-16% zirconium) and 5 ml of water were mixed, and 1.7 ml of 50% sodium hydroxide aqueous solution was added dropwise to obtain reaction solution A; 6.0 ml of Na2Si3O7 solution (containing about 12% silicon), 1.5 ml of 50% sodium hydroxide aqueous solution and 10 ml of water were mixed to obtain clear solution B;

[0140] The reaction solution A was added to the reaction solution B, and seed crystals were added, and then transferred to an autoclave for reaction at 240-250°C for about 58 hours, cooled and filtered, and the filter cake was washed with water and dried to obtain the product. The product was sent for XRPD inspection, and the XRPD inspection of the product showed that the main crystal form was ZS-9, which contained a small amount of impurity crystal forms ZS-7 and ZS-11, as in Comparative Example 2.

[0141] The above is an explanation of the exemplary embodiments of the present invention. However, the protection scope of the present invention is not limited to the above embodiments. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. A sodium zirconium cyclosilicate ZS-9 crystal, characterized in that: The crystal is a cubic crystal, the ratio between the length and width of the cubic crystal is 1:0.8 to 1:1.2, and the ratio between the length and height is 1:0.8 to 1:1.

2.

2. The sodium zirconium cyclosilicate ZS-9 crystal according to claim 1, characterized in that The crystal contains no less than 50% by mass, preferably 55%, preferably 60%, preferably 65%, preferably 70%, preferably 75%, preferably 80%, preferably 85%, preferably 90%, preferably 95% of the cubic crystals according to claim 1.

3. The sodium zirconium cyclosilicate ZS-9 crystal according to claim 1, characterized in that The average particle size of the cubic crystals is 0.5 μm-20 μm.

4. A method for preparing sodium zirconium cyclosilicate ZS-9 crystals, characterized in that: Specific additives are added during the conventional preparation process of ZS-9.

5. The preparation method according to claim 4, characterized in that: The additive is selected from one or more of anhydrous citric acid, citric acid monohydrate, tartaric acid, malic acid, glutamic acid, succinic acid, ethylenediaminetetraacetic acid, 4-aminobutyric acid, 1,3-propylenediamine and pharmaceutically acceptable salts thereof; preferably, the additive is selected from one or more of anhydrous citric acid, citric acid monohydrate, tartaric acid and malic acid.

6. The preparation method according to claim 4, characterized in that: The molar ratio of the additive to the zirconium reagent added in the conventional preparation method is 0.3:1 to 2.5:1, preferably 0.5:1 to 2.0:1, and more preferably 0.75:1 to 1.75:

1.

7. A method for preparing sodium zirconium cyclosilicate ZS-9 crystals, characterized in that: The preparation method comprises: mixing a zirconium reagent, an additive, a silicon reagent, sodium hydroxide and water into a solution, sealing and reacting at a high temperature, cooling and filtering after the reaction is completed, and obtaining sodium zirconium cyclosilicate ZS-9.

8. The preparation method according to claim 7, characterized in that: The zirconium reagent is selected from one or more of zirconium acetate solution, zirconium oxychloride octahydrate, zirconium chloride and zirconium sulfate tetrahydrate. Preferably, the zirconium reagent is selected from one or more of zirconium acetate solution and zirconium oxychloride octahydrate. Preferably, the additive is selected from one or more of anhydrous citric acid, citric acid monohydrate, tartaric acid, malic acid, glutamic acid, succinic acid, ethylenediaminetetraacetic acid, 4-aminobutyric acid, 1,3-propylenediamine and pharmaceutically acceptable salts thereof; preferably, the additive is selected from one or more of anhydrous citric acid, citric acid monohydrate, tartaric acid and malic acid; Preferably, the silicon reagent is selected from one or more of anhydrous Na2SiO3, Na2SiO3 hydrate, Na2SiO3 aqueous solution, anhydrous Na2Si3O7, Na2Si3O7 aqueous solution, and silicon dioxide; preferably, the silicon reagent is selected from silicon dioxide; Preferably, the molar ratio of the additive to the zirconium reagent is 0.3:1 to 2.5:1, preferably 0.5:1 to 2.0:1, and more preferably 0.75:1 to 1.75:1; Preferably, the molar ratio of the silicon reagent to the zirconium reagent is 3:1 to 10:1, preferably 3:1 to 6:1; Preferably, the molar ratio of the sodium hydroxide to the zirconium reagent is 2:1 to 18:1, preferably 7:1 to 14:1; The weight ratio of the water to the zirconium reagent is 2:1 to 20:1, preferably 5:1 to 15:

1.

9. The preparation method according to claim 7, characterized in that: The sealing reaction temperature at high temperature is 150-300° C., preferably 175-275° C.; the reaction time is 1-72 h, preferably 2-60 h, and more preferably 4-46 h.

10. The preparation method according to claim 7, characterized in that: Sodium zirconium cyclosilicate ZS-9 seed crystals were added to the reaction system.

Citation Information

Patent Citations

  • Microporous zirconium silicate for the treatment of hyperkalemia

    CN106385795A

  • Pharmaceutical compositions comprising ZS-9

    WO2019092179A1

Cited By

  • Cyclic zirconium sodium silicate composition as well as preparation method and application thereof

    CN121731342A

  • Sodium zirconium cyclosilicate with controlled particle size distribution and preparation method therefor

    WO2026194339A1